林业发展局批准口服糖尿病药物Rybelsus,以减少心脏病发作、中风和高危患者死亡。 FDA approves oral diabetes drug Rybelsus to reduce heart attacks, strokes, and death in high-risk patients.

美国食品和药物管理局批准了诺沃·诺迪斯(Novo Nordisk)的口服糖尿病药物Rybelsus(Rybelsus), 以减少高危2型糖尿病成年人的主要心血管疾病, The U.S. FDA has approved Novo Nordisk’s oral diabetes drug Rybelsus for reducing major cardiovascular events in adults with type 2 diabetes who are at high risk, based on a phase 3 trial showing a 14% reduction in heart attacks, strokes, or cardiovascular death over four years. 这标志着美国首次批准口服GLP-1受体激动剂用于心脏保护,为注射治疗提供基于药丸的替代方案. This marks the first approval of an oral GLP-1 receptor agonist for heart protection in the U.S., offering a pill-based alternative to injectable treatments. 该药物自2019年以来一直被核准用于血糖控制,其安全性与胃肠道副作用率略高的情况相符。 The drug, already approved since 2019 for blood sugar control, demonstrated consistent safety with slightly higher rates of gastrointestinal side effects. 该决定是在2025年初得到欧洲类似批准之后作出的。 The decision follows a similar European approval earlier in 2025.